Go 6976
(Synonyms: 5,6,7,13-四氢-13-甲基-5-氧代-12H-吲哚并[2,3-A]吡咯并[3,4-C]咔唑-12-丙腈,Go6976;Go-6976) 目录号 : GC15564
A PKCα/β1 inhibitor
Cas No.:136194-77-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment[1]: | |
|
Cell lines |
HEL cells |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
4 h, 1 µM |
|
Applications |
Go 6976 is a selective inhibitor of the calcium-dependent isozymes of protein kinase C (PKC) and has a direct and potent inhibitory effect on JAK2 in vitro. Go 6976 also blocked signalling, proliferation and survival in cells expressing TEL-JAK2 fusion protein. In primary acute myeloid leukaemia cells, treatment with Go 6976 reduced STAT phosphorylation and constitutive STAT activity. |
| Animal experiment [2]: | |
|
Animal models |
6-8 week-old Balb/c mice |
|
Dosage form |
2.5 mg/kg, i.p. |
|
Application |
Go 6976 significantly inhibited LPS-induced protein kinase D activation, relieved LPS/D-GalN-induced liver injury and improved the survival of LPS/D-GalN-administered mice. Go 6976 could also inhibit the activation of mitogen-activated protein kinases (MAPKs), reduce expression of tumor necrosis factor-a (TNF-ɑ), and decrease apoptosis and myeloperoxidase (MPO) activity in liver of mice. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Grandage V L, Everington T, Linch D C, et al. Go 6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells[J]. British journal of haematology, 2006, 135(3): 303-316. [2]. Duan G J, Zhu J, Xu C Y, et al. Protective effect of Go 6976, a PKD inhibitor, on LPS/d-GalN-induced acute liver injury in mice[J]. Inflammation research, 2011, 60(4): 357-366. |
|
Go 6976 is a selective inhibitor of PKC with IC50 value of 20 nM [1] [2].
Protein kinase C (PKC) is a family of protein kinase enzymes and plays an important role in controlling the function of other proteins by the phosphorylation of hydroxyl groups of serine and threonine amino acid residues on these proteins [1-3].
Go 6976 is a potent PKC inhibitor and has a more potent activity with the reported PKC inhibitor H-7. When tested with nRT cells, Go 6976 showed a marked decrease the baseline T-current amplitude nearly 40% at the dose of 10 μM by inhibiting Ca2+-dependent PKC pathway [3]. In T cell lines ACH-2 and U1 infected with HIV-1, Go 6976 treatment effectively blocked viral transcription induced by Bryostain 1 or tumor necrosis factor α which lead to the inhibition of intracellular viral protein synthesis and viral shedding and also blocked IL-6 mediated posttranscriptional inducetion of viral protein [2].
It is also reported that Go 6976 is a potent inhibitor to EGFR and FLT3with IC50 value ranges from 0.033 nM to 3.3 μM and 0.7 nM, respectively [4] [5].
References:
[1]. Gschwendt, M., et al., Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett, 1996. 392(2): p. 77-80.
[2]. Qatsha, K.A., et al., Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc Natl Acad Sci U S A, 1993. 90(10): p. 4674-8.
[3]. Joksovic, P.M., et al., Mechanisms of inhibition of T-type calcium current in the reticular thalamic neurons by 1-octanol: implication of the protein kinase C pathway. Mol Pharmacol, 2010. 77(1): p. 87-94.
[4]. Taube, E., et al., A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. Int J Cancer, 2012. 131(4): p. 970-9.
[5]. Yoshida, A., et al., Go6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1. Biochem Pharmacol, 2014. 90(1): p. 16-24.
| Cas No. | 136194-77-9 | SDF | |
| 别名 | 5,6,7,13-四氢-13-甲基-5-氧代-12H-吲哚并[2,3-A]吡咯并[3,4-C]咔唑-12-丙腈,Go6976;Go-6976 | ||
| 化学名 | 3-(13-methyl-5-oxo-6,7-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12(13H)-yl)propanenitrile | ||
| Canonical SMILES | O=C1NCC2=C3C(N(CCC#N)C4=CC=CC=C34)=C5N(C)C6=CC=CC=C6C5=C21 | ||
| 分子式 | C24H18N4O | 分子量 | 378.43 |
| 溶解度 | DMF: 10 mg/ml,DMF:PBS (pH 7) (1:10): 0.1 mg/ml,DMSO: 10 mg/ml | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6425 mL | 13.2125 mL | 26.425 mL |
| 5 mM | 0.5285 mL | 2.6425 mL | 5.285 mL |
| 10 mM | 0.2642 mL | 1.3212 mL | 2.6425 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。